Vivek
Pharmaceutical
Piramal
India
Biography
Mr. Vivek Sharma currently serves as the CEO of Piramal Pharma Solutions (PPS), a global leader in providing Contract Research, Development and Manufacturing services towards the life sciences industry. Piramal offers integrated solutions from discovery through development and commercialization, with research and manufacturing facilities in North America, Europe, and Asia. Under Vivek's leadership, Piramal has established itself as the 'partner of choice' for both large pharma and biotech firms. Vivek's focus on Quality, Reliability, and Customer Centricity has resulted in Piramal being voted as a 'global top 10% CMO' from 2014 through 2016. Vivek was also recognized as the global “CEO of the Year”, 2016, at CPhi Worldwide in Madrid. Vivek has led Piramal Pharma Solutions through rapid growth with a strategy that augments organic growth with synergistic, well timed, acquisitions. Internal investments in fast growing segments such as Antibody Drug Conjugate (ADC) manufacturing and hormonals, have been
Research Interest
Mr. Vivek Sharma currently serves as the CEO of Piramal Pharma Solutions (PPS), a global leader in providing Contract Research, Development and Manufacturing services towards the life sciences industry. Piramal offers integrated solutions from discovery through development and commercialization, with research and manufacturing facilities in North America, Europe, and Asia. Under Vivek's leadership, Piramal has established itself as the 'partner of choice' for both large pharma and biotech firms. Vivek's focus on Quality, Reliability, and Customer Centricity has resulted in Piramal being voted as a 'global top 10% CMO' from 2014 through 2016. Vivek was also recognized as the global “CEO of the Year”, 2016, at CPhi Worldwide in Madrid. Vivek has led Piramal Pharma Solutions through rapid growth with a strategy that augments organic growth with synergistic, well timed, acquisitions. Internal investments in fast growing segments such as Antibody Drug Conjugate (ADC) manufacturing and hormonals, have been
